ES2485940T3 - Combinación de vacunas contra Meningitis B/C - Google Patents

Combinación de vacunas contra Meningitis B/C Download PDF

Info

Publication number
ES2485940T3
ES2485940T3 ES06076647.4T ES06076647T ES2485940T3 ES 2485940 T3 ES2485940 T3 ES 2485940T3 ES 06076647 T ES06076647 T ES 06076647T ES 2485940 T3 ES2485940 T3 ES 2485940T3
Authority
ES
Spain
Prior art keywords
combination against
against meningitis
vaccination
vaccination combination
meningitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06076647.4T
Other languages
English (en)
Inventor
Dan M. Granoff
Ingeborg Aaberge
Bjorn Haneberg
Johan Holst
Howard Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORWEGIAN INSTITUTE OF PUBLIC HEALTH
NORWEGIAN INST OF PUBLIC HEALTH
Novartis Vaccines and Diagnostics Inc
Original Assignee
NORWEGIAN INSTITUTE OF PUBLIC HEALTH
NORWEGIAN INST OF PUBLIC HEALTH
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORWEGIAN INSTITUTE OF PUBLIC HEALTH, NORWEGIAN INST OF PUBLIC HEALTH, Novartis Vaccines and Diagnostics Inc filed Critical NORWEGIAN INSTITUTE OF PUBLIC HEALTH
Application granted granted Critical
Publication of ES2485940T3 publication Critical patent/ES2485940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición inmunogénica que comprende: i. Un oligosacárido del serogrupo C de Neisseria meningitidis conjugado a una proteína; ii. Una proteína de membrana externa del serogrupo B de Neisseria meningitidis, en la que la proteína de membrana externa se presenta como una vesícula proteoliposomal; y iii. un adyuvante. En la que dicha proteína conjugada al oligosacárido del serogrupo C es CRM197.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES06076647.4T 1998-05-29 1999-05-28 Combinación de vacunas contra Meningitis B/C Expired - Lifetime ES2485940T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8735198P 1998-05-29 1998-05-29
US87351P 1998-05-29
US10644698P 1998-10-30 1998-10-30
US106446P 1998-10-30

Publications (1)

Publication Number Publication Date
ES2485940T3 true ES2485940T3 (es) 2014-08-14

Family

ID=26776879

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06076647.4T Expired - Lifetime ES2485940T3 (es) 1998-05-29 1999-05-28 Combinación de vacunas contra Meningitis B/C
ES99926046T Expired - Lifetime ES2278446T3 (es) 1998-05-29 1999-05-28 Vacunas combinadas b/c contra la meningitis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99926046T Expired - Lifetime ES2278446T3 (es) 1998-05-29 1999-05-28 Vacunas combinadas b/c contra la meningitis.

Country Status (15)

Country Link
US (1) US8007815B1 (es)
EP (2) EP2796148A3 (es)
JP (2) JP5074644B2 (es)
AT (1) ATE346609T1 (es)
AU (2) AU761495B2 (es)
BR (1) BR9910749A (es)
CA (1) CA2332963C (es)
CY (1) CY1107550T1 (es)
DE (1) DE69934225T2 (es)
DK (1) DK1079857T3 (es)
ES (2) ES2485940T3 (es)
HK (1) HK1034460A1 (es)
NZ (1) NZ508771A (es)
PT (2) PT1079857E (es)
WO (1) WO1999061053A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
ES2485940T3 (es) 1998-05-29 2014-08-14 Novartis Vaccines And Diagnostics, Inc. Combinación de vacunas contra Meningitis B/C
CN102580072A (zh) 1999-05-19 2012-07-18 诺华疫苗和诊断有限公司 组合式奈瑟球菌组合物
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2507100T3 (es) * 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0115176D0 (en) † 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MXPA04000653A (es) 2001-07-27 2004-11-22 Chiron Srl Adhesinas de meningococcus nada, app y orf 40.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CN103405761A (zh) * 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP2462949A3 (en) * 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
CN104650241A (zh) * 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
JP6324961B2 (ja) * 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
ES2128055T3 (es) 1994-04-20 1999-05-01 Us Army Vacuna contra infecciones de bacterias gram-negativas.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ES2485940T3 (es) 1998-05-29 2014-08-14 Novartis Vaccines And Diagnostics, Inc. Combinación de vacunas contra Meningitis B/C
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗

Also Published As

Publication number Publication date
ES2278446T3 (es) 2007-08-01
NZ508771A (en) 2003-08-29
CA2332963A1 (en) 1999-12-02
BR9910749A (pt) 2001-02-13
DE69934225D1 (de) 2007-01-11
US8007815B1 (en) 2011-08-30
JP5074644B2 (ja) 2012-11-14
WO1999061053A1 (en) 1999-12-02
JP2009292851A (ja) 2009-12-17
DE69934225T2 (de) 2007-09-27
ATE346609T1 (de) 2006-12-15
DK1079857T3 (da) 2007-01-29
CY1107550T1 (el) 2013-03-13
EP2796148A2 (en) 2014-10-29
AU2003244518A1 (en) 2003-09-25
AU4221599A (en) 1999-12-13
EP1079857A1 (en) 2001-03-07
CA2332963C (en) 2013-07-23
EP1079857B1 (en) 2006-11-29
PT1741443E (pt) 2014-07-31
PT1079857E (pt) 2007-02-28
AU761495B2 (en) 2003-06-05
JP2002516292A (ja) 2002-06-04
HK1034460A1 (en) 2001-10-26
EP2796148A3 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2485940T3 (es) Combinación de vacunas contra Meningitis B/C
ES2361993T5 (es) Tratamiento con enzimas de productos alimenticios para celiaquía
LU91734I2 (fr) Menveo - oligosaccharide méningococcique du group Y conjugué à la protéine CRM197 de Corynebacteriumdiphteriae.
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
DE60038252D1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
BR0016022A (pt) Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
DE60233401D1 (de) Medizinisches exzisions- und ultraschall-behandlungssystem
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn's disease using the ompc antigen
DE60032250D1 (de) Behandlung von Allergien
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
CY1106092T1 (el) Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
FR2720408B1 (fr) Fragments Tbp2 de Neisseria meningitidis.
NO20040611L (no) Ekspanderbar gastrisk retensjonsanordning.
ATE207295T1 (de) Fungizide mischungen
EP1741443A3 (en) Combination meningitidis B/C vaccines
IT236066Y1 (it) Trasduttore di pressione per linee sangue utilizzate nel trattamentodialitico.
SE9902674D0 (sv) New composition
Popowski et al. Presence of two epiphytic dinoflagellates in two areas of Cancun, Mexico].
RU95108615A (ru) Минипластинка для устранения посттравматических дефектов и деформаций нижней стенки глазницы
ES2127133B1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
IT1318985B1 (it) Specola divaricabile per trattamenti idroterapeutici dell'intestino.